These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22538363)

  • 21. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
    Hernández-Marqués C; Lassaletta-Atienza A; Ruiz Hernández A; Blumenfeld Olivares JA; Arce Abaitua B; Cormenzana Carpio M; Madero Lopez L
    An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
    Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
    Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective experience of children with relapsed brain tumors treated with oral combination of axitinib and metronomic etoposide.
    Donzé C; Revon-Rivière G; Pondrom M; Verschuur A; Leblond P; André N
    Pediatr Blood Cancer; 2024 Aug; 71(8):e31076. PubMed ID: 38778441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.
    Perroud HA; Rico MJ; Alasino CM; Queralt F; Mainetti LE; Pezzotto SM; Rozados VR; Scharovsky OG
    Future Oncol; 2013 Mar; 9(3):451-62. PubMed ID: 23469980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
    Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
    Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
    Traore F; Togo B; Pasquier E; Dembélé A; André N
    Indian J Cancer; 2013; 50(3):250-3. PubMed ID: 24061467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
    Porkholm M; Valanne L; Lönnqvist T; Holm S; Lannering B; Riikonen P; Wojcik D; Sehested A; Clausen N; Harila-Saari A; Schomerus E; Thorarinsdottir HK; Lähteenmäki P; Arola M; Thomassen H; Saarinen-Pihkala UM; Kivivuori SM
    Pediatr Blood Cancer; 2014 Sep; 61(9):1603-9. PubMed ID: 24692119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease?
    Padovani L; Andre N; Gentet JC; Figarella Branger D; Scavarda D; Verschuur A; Chinot O; Cowen D; Muracciole X
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):600-4. PubMed ID: 22042276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor.
    Heng-Maillard MA; Verschuur A; Aschero A; Dabadie A; Jouve E; Chastagner P; Leblond P; Aerts I; De Luca B; André N
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27693. PubMed ID: 30920117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
    Seiz M; Kohlhof P; Brockmann MA; Neumaier-Probst E; Hermes P; VON Deimling A; Vajkoczy P; Schmieder K; Tuettenberg J
    Anticancer Res; 2009 Aug; 29(8):3261-7. PubMed ID: 19661344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Zustovich F; Landi L; Lombardi G; Porta C; Galli L; Fontana A; Amoroso D; Galli C; Andreuccetti M; Falcone A; Zagonel V
    Anticancer Res; 2013 Aug; 33(8):3487-94. PubMed ID: 23898124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
    Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
    Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
    McNall-Knapp RY; Williams CN; Reeves EN; Heideman RL; Meyer WH
    Pediatr Blood Cancer; 2010 Jul; 54(7):909-15. PubMed ID: 20405511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
    Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
    Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
    Gadgeel SM; Ruckdeschel JC; Heath EI; Heilbrun LK; Venkatramanamoorthy R; Wozniak A
    J Thorac Oncol; 2007 Apr; 2(4):299-305. PubMed ID: 17409801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.